StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)
StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after buying an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. 59.25% of the stock is owned by hedge funds and other institutional investors. Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note issued to investors on Friday. The brokerage set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的股票研究人员在周五发布给投资者的一份研究报告中开始报道Genocea Biosciences(纳斯达克：GNCA-GET评级)的股票。该经纪公司对这家生物技术公司的股票设定了“卖出”评级。
Several other equities analysts also recently issued reports on GNCA. Stifel Nicolaus downgraded shares of Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th. HC Wainwright downgraded shares of Genocea Biosciences from a "buy" rating to a "neutral" rating in a research note on Friday, April 29th. Finally, Robert W. Baird lowered their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th.
其他几位股票分析师最近也发布了关于GNCA的报告。Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的股票评级从“买入”下调至“持有”。在4月29日星期五的一份研究报告中，HC Wainwright将Genocea Biosciences的股票评级从“买入”下调至“中性”。最后，罗伯特·W·贝尔德在4月11日星期一的一份研究报告中将Genocea Biosciences的目标股价从8.00美元下调至3.00美元。
Shares of NASDAQ:GNCA opened at $0.01 on Friday. The company has a market cap of $828,149.40, a price-to-earnings ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $0.10 and a 200 day simple moving average of $0.69. Genocea Biosciences has a one year low of $0.01 and a one year high of $2.24.
纳斯达克：GNCA的股票周五开盘报0.01美元。该公司市值为828,149.40美元，市盈率为-0.02，贝塔系数为2.26。该公司的债务权益比为0.24，流动比率为1.35，速动比率为1.35。该公司的50日简单移动均线切入位为0.10美元，200日简单移动均线切入位为0.69美元。Genocea Biosciences的一年低点为0.01美元，一年高位为2.24美元。
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after buying an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. 59.25% of the stock is owned by hedge funds and other institutional investors.
一家对冲基金最近增持了Genocea Biosciences股票。据最近提交给美国证券交易委员会的文件显示，Federal Equity Services LLC在第四季度将其在Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET评级)的股票持仓量提高了49.4%。该基金持有这家生物技术公司31,981股股票，在本季度又购买了10,576股。截至最近向美国证券交易委员会提交的文件，英联邦股权服务公司拥有Genocea Biosciences公司约0.06%的股份，价值3.7万美元。59.25%的股票由对冲基金和其他机构投资者持有。
About Genocea Biosciences (Get Rating)
关于Genocea生物科学(获取评级)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
- Is Roblox A Good Play For The 2nd Half
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 信实科技股正在反弹
- 投资优先股与普通股
- 从52周低点的股票中获利
- 内部人士正在买入的三只廉价股票
- 罗伯克斯是下半场的好球员吗？
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
